Clinical Trial Update: Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docetaxel for persistent or recurrent cervical cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Carcinoma
• Cervical Squamous Cell Carcinoma Not Otherwise Specified

Drugs mentioned

• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma | Phase 2 | Status: COMPLETED